Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group

Blood

Volumn 94, Issue 5, 1999, Pages 1537-1544

  Heerema, Nyla A ^a   Sather, Harland N ^b   Sensel, Martha G ^b   Liu Mares, Wen ^b   Lange, Beverly J ^b   Bostrom, Bruce C ^b   Nachman, James B ^b   Steinherz, Peter G ^b   Hutchinson, Raymond ^b   Gaynon, Paul S ^b   Arthur, Diane C ^b   Uckun, Fatih M ^b  

^a CHILDREN S ONCOLOGY GROUP   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; CHILD; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME INVERSION 9; CHROMOSOME TRANSLOCATION 9; CONTROLLED STUDY; DICENTRIC CHROMOSOME; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK FACTOR; TREATMENT FAILURE;

CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 13044266372     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Chilcote RR, Brown E, Rowley JD: Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9. N Engl J Med 313:286, 1985
2. Carroll AJ, Castleberry RP, Crist WM: Lack of association between abnormalities of the chromosome 9 short arm and either "lymphomatous" features or T cell phenotype in childhood acute lymphocytic leukemia. Blood 69:735, 1987
3. Kowalczyk J, Sandberg AA: A possible subgroup of ALL with 9p-. Cancer Genet Cytogenet 9:383, 1983
4. Pollak C, Hagemeijer A: Abnormalities of the short arm of chromosome 9 with partial loss of material in hematological disorders. Leukemia 1:541, 1987
5. Murphy SB, Raimondi SC, Rivera GK, Crone M, Dodge RK, Behm FG, Pui CH, Williams DL: Nonrandom abnormalities of chromosome 9p in childhood acute lymphoblastic leukemia: Association with high-risk clinical features. Blood 74:409, 1989
6. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Williams DL, Murphy S, Dahl G, Kalwinsky D, Evans W, Kun L, Simone J, Crist W: Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61, 1991
7. Behrendt H, Charrin C, Gibbons B, Harrison CJ, Hawkins JM, Heerema NA, Horschler-Botel B, Huret JL, Lai JL, Lampert F, Nelken B, Perot C, Ritterbach J, Schlegelberger B, Secker-Walker L, Slater R, Slovak M, Tanzer J, Van Den Akker J: Dicentric (9; 12) in acute lymphocytic leukemia and other hematological malignancies: Report from a dic(9;12) study group. Leukemia 9:102, 1995
8. Mahmoud H, Carroll AJ, Behm F, Raimondi SC, Schuster J, Borowitz M, Land V, Pullen DJ, Vietti TJ, Crist W: The non-random dic(9;12) translocation in acute lymphoblastic leukemia is associated with B-progenitor phenotype and an excellent prognosis. Leukemia 6:703, 1992
9. Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa R III, Dreyling MH, Gursky S, Stadler WM, Le Beau MM, Bohlander SK: Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci USA 92:6489, 1995
10. Diaz MO, Ziemin S, Le Beau MM, Pitha P, Smith SD, Chilcote RR, Rowley JD: Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA 85:5259, 1988
11. Diaz M, Rubin C, Harden A, Ziemin S, Larson R, Le Beau M, Rowley J: Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med 322:77, 1990
12. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436, 1994
13. Weaver-Feldhaus J, Gruis NA, Neuhausen S, Le Paslier D, Stocken E, Skolnick MH, Kamb A: Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc Natl Acad Sci USA 91:7563, 1994
14. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753, 1994
15. Zhou M, Gu L, Yeager AM, Findley HW: Incidence and clinical significance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 14:141, 1997
16. Diccianni MB, Batova A, Yu J, Vu T, Pullen J, Amylon M, Pollock BH, Yu AL: Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. Leuk Res 21:549, 1997
17. Kees UR, Burton PR, Lu C, Baker DL: Homozygous deletion of the p16/MTS1 gene in pédiatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood 89:4161, 1997
18. Rubnitz JE, Behm FG, Pui CH, Evans WE, Relling MV, Raimondi SC, Harrison PL, Sandlund JT, Ribeiro RC, Grosveld G, Downing JR: Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: Results of St Jude Total Therapy Study XII. Leukemia 11:1201, 1997
19. Drexler HG: Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12:845, 1998
20. Okuda T, Shurtleff S, Valentine M, Raimondi S, Head D, Behm F, Curcio-Brint A, Liu Q, Pui C, Sherr C, Beach D, Look A, Downing J: Frequent deletion of p16INK4a/MTS1 and p15INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 85:2321, 1995
21. Uckun FM, Muraguchi A, Ledbetter JA, Kishimoto T, O'Brien RT, Roloff JS, Gajl Peczalska K, Provisor A, Koller B: Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood 73:1000, 1989
22. Smith M, Arthur D, Camilla B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18, 1996
23. Steinherz PG, Siegel SE, Bleyer WA, Kersey J, Chard R Jr, Coccia P, Leiken S, Lukens J, Neerhout R, Nesbit M, Miller DR, Reaman G, Sather H, Hammond D: Lymphomatous presentation of childhood acute lymphoblastic leukemia. Cancer 68:751, 1991
24. Heerema NA, Arthur DC, Sather H, Albo V, Feusner J, Lange BJ, Steinherz PG, Zeltzer P, Hammond D, Reaman GH: Cytogenetic features of infants less than 12 months of age at diagnosis of acute lymphoblastic leukemia: Impact of the 11q23 breakpoint on outcome: A report of the Childrens Cancer Group. Blood 83:2274, 1994
25. Pui CH, Kane JR, Crist WM: Biology and treatment of infant leukemias. Leukemia 9:762, 1995
26. Reaman G, Zeltzer P, Bleyer WA, Amendola B, Level C, Sather H, Hammond D: Acute lymphoblastic leukemia in infants less than one year of age: A cumulative experience of the Children's Cancer Study Group. J Clin Oncol 3:1513, 1985
27. Heerema N, Sather H, Ge J, Arthur D, Hilden J, Trigg M, Reaman G: Cytogenetic studies of infant acute lymphoblastic leukemia: Poor prognosis of infants with t(4;11): A report of the Children's Cancer Group. Leukemia 13:679, 1999
28. Heerema NA, Palmer CG, Baehner RL: Karyotypic and clinical findings in a consecutive series of children with acute lymphocytic leukemia. Cancer Genet Cytogenet 17:165, 1985
29. Mitelman F (ed): ISCN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, Karger, 1995
30. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
31. Peto R, Pike MC, Armitage P, Breslow N, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II. Analysis and examples. Br J Cancer 35:1, 1977
32. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
33. Breslow N: Analysis of survival data under the proportional hazards model. Int Stat Rev 43:45, 1975
34. Cox DR: Regression models and life tables. J R Stat Soc B 34:187, 1972
35. Kalbfleisch J, Prentice R: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
36. Gaynor J, Feuer E, Tan C, Wu D, Little C, Straus D, Clarkson B, Brennan M: On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 88:400, 1993
37. Gray R: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141, 1988
38. Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Reaman GH, Sather HN, Steinherz PG, Trigg ME, Tubergen DG, Uckun FM: Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review. Cancer 80:1717, 1997
39. Lange B, Sather H, Weetman R, Bostrom B, McGuire P, Rackoff W, Arthur D, Trigg M: Double delayed intensification improves outcome in moderate risk pediatric acute lymphoblastic leukemia (ALL): A Children's Cancer Group study, CCG-1891. Blood 90:559a, 1997
40. Bostrom B, Gaynon P, Sather H, Gold S, Hutchinson R, Provisor A, Trigg M: Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improves event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL). Proc Am Soc Clin Oncol 17:527a, 1998